Boehringer Ingelheim has introduced the latest innovation in Marek’s disease vaccines to the Indian market, marking a significant advancement. This state-of-the-art vaccine utilizes a unique controlled attenuation technique, ensuring a superior balance of protection and safety.
Marek’s disease continues to challenge poultry farming in India, with outbreaks persisting despite existing vaccination strategies. This novel serotype-1 vaccine effectively tackles this issue by offering unmatched safety and efficacy against the most aggressive virus strains.
Dr. Vinod Gopal, Head of Animal Health at Boehringer Ingelheim India, stated that Marek’s disease poses a serious threat, leading to notable economic losses for poultry farmers, especially impacting young chicks with underdeveloped immune systems. As the nation’s poultry sector grows, this vaccine is poised to support farmers by curbing disease incidents, boosting poultry well-being, and enhancing productivity. It ensures strong, early, and sustained immunity, validated through comprehensive trials in different regions, while also contributing significantly to food security and safety. This cost-effective solution aids poultry producers in safeguarding their livelihood amid increasing demands for premium poultry products across India.
Dr. N.K Mahajan, Former Head of the Department of Veterinary Public Health and Epidemiology, LUVAS, Hisar, explained that Marek’s disease remains a formidable challenge due to the virus’s evolving virulence. Even without evident symptoms, the virus severely compromises the chickens’ immune systems by targeting T lymphocytes. This leads to immunosuppression, hampering growth and performance, which adversely affects poultry production and economics. Birds become more susceptible to secondary infections and respond poorly to other vaccines, resulting in higher medication costs. Providing early immunity against more virulent virus strains is vital to mitigating the adverse effects on poultry farming in India.
The connection between animal and human health is intricate and profound. Healthy animals contribute to healthier humans globally. Our dedicated team of 9,700 employees strives to create value and enhance well-being through innovation.
Animal welfare, human health, and environmental respect form the core of our mission. We develop solutions and services to shield animals from disease and discomfort, helping our clients maintain animal health and protect communities from critical health threats.
Boehringer Ingelheim Animal Health ranks as the world’s second-largest animal health enterprise, achieving sales of 4.1 billion euros in 2020, and is operational in over 150 nations.
Established in 1885, Boehringer Ingelheim is a prominent biopharmaceutical firm offering pioneering treatments for both humans and animals. With a global workforce of 53,000, it operates across 130 markets focusing on human pharmaceuticals, animal health, and contract biopharmaceutical manufacturing.